CORRESPONDENCE
T-lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies TO 
THE EDITOR
Analysis of minimal residual disease (MRD) during the first phases of treatment can predict outcome in children with acute lymphoblastic leukemia (ALL). 1 Sensitive MRD detection is possible in the majority of ALL patients by PCR analysis of clonal rearrangements of immunoglobulin (Ig) and T cell receptor (TCR) genes. 2 The sensitivity of these PCR targets however is at least partly dependent on the frequency of comparable gene rearrangements in normal cells. This is particularly true for TCR gamma (TCRG) gene rearrangements, because they occur on both alleles in virtually all CD3
+ T-lymphocytes and show limited combinatorial and junctional diversity. Since TCRG gene rearrangements occur in approximately 55% of precursor-B-ALL and in approximately 90% of T-ALL, they are however widely used as PCR targets in MRD studies of ALL patients. 2, 3 Recently, Delabesse et al 4 reported their rapid and elegant multifluorescent TCRG V␥ and J␥ gene scanning for detection of moderate levels of MRD without the usage of junctional region specific oligonucleotides. For sensitivity testing, they evaluated six TCRG gene rearrangements from three T-ALLs by multiplex and V␥-J␥ specific direct fluorescent PCR in dilution experiments using DNA from a mixture of 10% peripheral blood (PB) in the U937 myeloid cell line to simulate early remission bone marrow conditions. We wonder whether this is the correct test condition for sensitivity testing, because such an artificial mixture of 10% PB contains only 6-8% CD3 + Tlymphocytes. In normal bone marrow (BM) the mean frequency of CD7 + cells is indeed 7.9 ± 1.8% in children less than 14 years of age and ±86% of them are CD3 + T-lymphocytes. 5 However, BM samples obtained during and after chemotherapy for ALL in children differ significantly from normal BM samples, particularly just after induction treatment. 6 We studied 57 childhood precursor-B-ALL patients (aged: 0-16 years), who remained in continuous complete remission with a median follow-up time of 5 years. All children received the ALL-8 protocol of the Dutch Childhood Leukemia Study Group (DCLSG), which had a BFM-therapy backbone. BM and PB samples were all sent to the central laboratory of the DCLSG for confirmation and classification of diagnosis and for follow-up at 18 well-defined time points during and after treatment by use of cytomorphology and flowcytometric immunophenotyping. A total of 640 BM samples of these 57 ALL patients were analyzed. Mononuclear cells (MNC) were isolated from BM by Ficoll-Paque centrifugation. The percentage of T-lymphocytes was assessed with the CD3 (Leu-4) antibody via analysis on a FACScan flow cytometer using Lysis II software (Becton Dickinson, San Jose, CA, USA). Gating was set on forward-and sidescatter parameters to exclude cellular debris. The frequencies of CD3 + cells were expressed as percentages of total MNC analysed ( Figure 1 ). The highest frequencies of T-lymphocytes were found 4 weeks after the start of induction treatment: mean of 38% (median 37%, with 10 and 90 percentiles of 23% and 56%, respectively). During therapy and thereafter, the mean percentage of CD3 positivity was much lower and varied between 10% and 16% (median between 8% and 16% and 10-90 percentiles range: 3%-32%).
Our data show that the percentages of CD3 + T-lymphocytes in BM samples obtained during treatment are generally higher than in normal BM. These high T-lymphocyte frequencies are particularly observed during and after induction treatment, when hematopoiesis and BM Percentages of CD3 + T-lymphocytes in BM samples during and after treatment with the DCLSG-ALL 8 protocol. The black dots indicate the median values, whereas the gray bars are the 10 to 90 percentiles of CD3 + T-lymphocytes at each sampling time point.
cellularity are low. Notably, MRD detection during this early phase of treatment will be used to recognise patients with good or poor prognosis and for MRD-based risk group stratification.
1 Apparently blood contamination of BM samples cannot be avoided when they are taken during a therapy-induced hypoplastic phase. This implies that during and after induction treatment TCRG-based MRD-PCR detection without junctional region specific oligonucleotides cannot easily reach the low sensitivity of 5 × 10 −3 , as assumed by Delabesse et al. 4 Consequently, it will not be possible to recognise the MRD-based low risk patients and also some MRD-based high risk patients might be missed. first, the percentage of T lymphocytes present in complete remission bone marrow aspirates at the end of induction therapy and second, the capacity of fluorescent gene scan analysis without junction specific probes to reproducibly achieve a 5 × 10 −3 level of sensitivity of detection.
With regard to the proportion of T lymphocytes in early complete remission bone marrow, this is obviously determined by the extent of dilution by peripheral blood, which is, in turn, determined by the volume of marrow aspirated. While we accept that hemodilution is more likely in early remission samples, we are surprised at the mean 38% CD3 positivity described by van Wering, albeit analyzed on a gated population. Morphological assessment of approximately day 35 bone marrow samples from 32 children treated on the French FRALLE93 protocol showed a median lymphocyte count of 9.5%, mean 14%, range 0-67%. This difference is unlikely to be protocolbased since both are BFM-based, and is more likely to result from the different analytical procedures and/or the extent of hemodilution. As a measure of the latter, we have compared the proportion of erythroblasts and lymphocytes. Morphologically, erythroid cells represented on average 42% (median 37%; range 3-72% ) of nucleated cells, in keeping with relatively limited hemodilution. It would be interesting to compare these data with the immunophenotypic estimate of the proportion of erythroid precursors in the Ficolled fractions analyzed by van Wering et al.
We are well aware that the presence of polyclonal T lymphocytes reduces the sensitivity of detection of a clonal population, 2 but do not agree that the strategies described in Delabesse et al 1 cannot reproducibly achieve a sensitivity of 5 × 10 −3 in early remission marrow. Direct comparison of a diagnostic ALL TCRG Vfi-JP1/2 rearrangement diluted in parallel into a 10% PBL/90% myeloid DNA mix, into the patients own day 35 bone marrow and into a day 35 marrow from another individual showed a level of detection below 5 × 10 −3 in all three situations, albeit with improved sensitivity in the 10% PBL mix. Furthermore, it should be emphasized that the data presented in Delabesse et al was primarily intended as a comparative analysis of the use of consensus vs VG-specific primers in multiplex vs monoplex PCR strategies. As stated in the manuscript, 'the VG-JG-specific fluorescent PCR analyses were not optimised to maximise specificity, being used under multiplex conditions. It is therefore possible that their potential sensitivity is higher'. In keeping with this, since optimising monoplex fluorescent genescan analysis in collaboration with H Cavé (H Guidal, H Cavé et al, manuscript submitted), we have analyzed day 27-63 bone marrows from 28 ALLs, including 19 children. Diagnostic blasts are evaluated after Ficol-Hypaque separation and their sensitivity of detection evaluated after dilution into either the patients . Not surprisingly, all five alleles demonstrating insufficient sensitivity at 5 × 10 −3 or more belong to the predominant VGfI, when competition with polyclonal rearrangements is maximal. We are aware that these strategies will not be appropriate for the identification of patients at a potentially extremely low risk of relapse, as identified by van Dongen et al. 3 We do, however, consider that, with appropriate precautions to determine sensitivity of individual rearrangements, the simplified strategies which we have described represent a valid alternative to junction specific strategies for the prospective detection at remission induction of patients at a high risk of relapse, in whom a cut-off of 10 −2 has been shown to suffice. 4 Only prospective incorporation of different molecular follow-up strategies into current protocols will determine which are best adapted to therapeutic stratification based on individual patient risk. 
